N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

Findings from pediatric trials showed left ventricular opacification with Definity was successful and provided important information to guide patient management. The Food and Drug Administration (FDA) ...

Lantheus Medical Imaging announced that the Food and Drug Administration (FDA) has approved a label update for Definity (perflutren lipid microsphere) injectable suspension with the removal of a ...

BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc. (“Lantheus”) today announced U.S. Food and Drug Administration (FDA) approval of an important label update for DEFINITY ® Vial ...

October 15, 2007 (Rockville, MD)-As expected, the US FDA has requested that a boxed warning be added to the labeling of two contrast agents used in echocardiography: perflutren liquid microspheres ...

Wilmington, DE -DuPont Pharmaceuticals announced today they have received FDA approval for their Definity? (Perflutren Lipid Microsphere) ultrasound contrast agent. Definity is used to improve the ...

Please provide your email address to receive an email when new articles are posted on . Lantheus Medical Imaging Inc. announced that the FDA has approved a label update that removes the ...